Mental Health Clinics in Grant, MI Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Era Counseling Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1357 E Hess Lake Dr, Grant, MI 49327 Phone: 734-883-8415 Fax: 734-822-0199 |
Newaygo County General Hospital Association Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 230 S Maple St, Grant, MI 49327 Phone: 231-834-5995 |
Grant High School Behavioral Health Services Counselor - Professional Medicare: Medicare Enrolled Practice Location: 331 E State Rd Rm N8, Grant, MI 49327 Phone: 231-834-5622 Fax: 231-745-3690 |
News Archive
Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial
Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.
News outlets examine what you should know about new health law provisions
USA Today, on how the new health law has started helping consumers: "Provisions of the health care reform law that took effect Sept. 23 prohibit some of the industry's most controversial practices." Insurers must now cover children with pre-existing conditions and cover preventive care for everyone.
IQWiG investigates benefits of rilpivirine for HIV treatment
Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant-) and by the other as a fixed combination with other HIV drugs (trade name Eviplera-).
Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment
Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.
› Verified 7 days ago